| Lung Cancer Treatments and Mutations | Lifetime | 53 | IT 1 | 99.82 |
| Lymphoma Diagnosis and Treatment | Lifetime | 42 | IT 4 | 99.80 |
| Cancer Mechanisms and Therapy | Lifetime | 27 | IT 1 | 99.45 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 81 | IT 5 | 99.63 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 196 | IT 5 | 99.50 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 178 | IT 14 | 99.46 |
| Colorectal Cancer Treatments and Studies | Lifetime | 161 | IT 14 | 99.45 |
| Sarcoma Diagnosis and Treatment | Lifetime | 169 | IT 12 | 99.20 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 48 | IT 5 | 99.34 |
| Vascular Tumors and Angiosarcomas | Lifetime | 52 | IT 8 | 99.18 |
| Lung Cancer Research Studies | Lifetime | 252 | IT 20 | 98.94 |
| Liver physiology and pathology | Lifetime | 137 | IT 9 | 98.61 |
| Cancer Treatment and Pharmacology | Lifetime | 369 | IT 28 | 98.92 |
| Occupational and environmental lung diseases | Lifetime | 132 | IT 11 | 98.24 |
| Viral-associated cancers and disorders | Lifetime | 269 | IT 17 | 98.40 |
| CAR-T cell therapy research | Lifetime | 507 | IT 23 | 98.55 |
| Pleural and Pulmonary Diseases | Lifetime | 225 | IT 11 | 98.02 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 930 | IT 69 | 98.07 |
| Peptidase Inhibition and Analysis | Lifetime | 814 | IT 29 | 97.43 |
| Multiple and Secondary Primary Cancers | Lifetime | 264 | IT 25 | 97.27 |
| Neuroendocrine Tumor Research Advances | Lifetime | 670 | IT 69 | 97.84 |
| HER2/EGFR in Cancer Research | Lifetime | 515 | IT 33 | 97.89 |
| Cardiac tumors and thrombi | Lifetime | 408 | IT 39 | 96.32 |
| Advanced Breast Cancer Therapies | Lifetime | 545 | IT 40 | 95.75 |
| Brain Metastases and Treatment | Lifetime | 971 | IT 37 | 94.50 |
| Myasthenia Gravis and Thymoma | Lifetime | 794 | IT 79 | 92.17 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 815 | IT 76 | 88.53 |
| Chemotherapy-related skin toxicity | Lifetime | 541 | IT 32 | 86.22 |
| Male Breast Health Studies | Lifetime | 390 | IT 48 | 71.89 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 180 | IT 16 | 99.30 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 77 | IT 5 | 99.07 |
| CAR-T cell therapy research | 2021-2025 | 372 | IT 11 | 97.55 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 47 | IT 4 | 96.86 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 303 | IT 44 | 96.19 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 436 | IT 56 | 95.50 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 697 | IT 48 | 95.75 |
| Advanced Breast Cancer Therapies | 2021-2025 | 238 | IT 22 | 95.75 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 575 | IT 47 | 94.36 |
| Cancer-related Molecular Pathways | 2021-2025 | 173 | IT 7 | 90.83 |
| HER2/EGFR in Cancer Research | 2021-2025 | 343 | IT 30 | 94.30 |
| Lung Cancer Research Studies | 2021-2025 | 824 | IT 72 | 91.05 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 1,000 | IT 26 | 88.55 |
| Cancer Treatment and Pharmacology | 2021-2025 | 721 | IT 52 | 87.30 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 423 | IT 23 | 84.12 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 272 | IT 38 | 85.98 |
| Viral-associated cancers and disorders | 2021-2025 | 671 | IT 34 | 82.66 |
| Occupational and environmental lung diseases | 2021-2025 | 799 | IT 95 | 72.14 |
| TGF-β signaling in diseases | 2021-2025 | 326 | IT 11 | 49.73 |
